- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Nycomed rumored as acquisition target
Norwegian contrast developer Hafslund Nycomed is again being mentionedas a possible merger or acquisition target. Several drug industryanalysts believe that the Oslo firm will be one of the next companiesto take part in the pharmaceutical industry's
Norwegian contrast developer Hafslund Nycomed is again being mentionedas a possible merger or acquisition target. Several drug industryanalysts believe that the Oslo firm will be one of the next companiesto take part in the pharmaceutical industry's ongoing consolidation,according to Reuters.
Rumors of an impending merger or acquisition of Nycomed havesurfaced before. The company was reported to be examining an alliancewith Sweden's Pharmacia last year, but in fact Nycomed was planninga merger with generic drug developer Ivax (SCAN 10/25/95 and 12/13/95).That deal later fell apart due to opposition from Nycomed shareholders.
Several large pharmaceutical companies are eying acquisitionsin the Nordic region, according to Reuters. German pharmaceuticalcompany GEHE AG reportedly is interested in acquiring Nycomed,the wire service reported. Nycomed officials declined to commenton the speculation.
In other Nycomed news, the company said that American HealthServices has canceled a contrast agent supply agreement for Nycomedproducts. American Health Services is now part of a larger purchasinggroup and has signed a supply agreement with another contrastprovider, Nycomed said.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
